Skip to main navigation

Skip to content

Customer Service: 866-788-9007

PHYSICIAN LOGIN | CRF LOGIN

ORDER TEST

Company
Products
Research & Development
Investors
Scientific Publications
Resources

January 9, 2020 Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2019 Performance Results, Delivering 29% DecisionDx-Melanoma Test Report Volume Growth in 2019

Email Alerts

Email Alerts

Required fields denoted by an asterisk ().

Alert type
Quote
SEC Filing
End of the Day SEC Filing
Event
News

Email

Latest News

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2019 Performance Results, Delivering 29% DecisionDx-Melanoma Test Report Volume Growth in 2019 January 9, 2020
Castle Biosciences Announces Level of Evidence Review on DecisionDx-Melanoma Published in Latest Issue of American Journal of Clinical Dermatology December 30, 2019
Castle Biosciences Added to NASDAQ Biotechnology Index December 18, 2019
Castle Biosciences Announces Time Change for Presentation at the Evercore ISI Second Annual HealthCONx December 3, 2019
Castle Biosciences Presents Expanded Data Supporting Use of DecisionDx-Melanoma Test to Inform Sentinel Lymph Node Biopsy Recommendations November 25, 2019

Site - Investor Tools

Print Page

RSS Feeds

Email Alerts

Investor Contact

Investor Contact

Search

Connect with Us

Company

About Us
History
Leadership
- Executive Management
- Board of Directors
Licenses
Careers
Contact Us

Products

Cutaneous Melanoma
- DecisionDx-Melanoma
- DecisionDx-CMSeq
Uveal Melanoma

Research & Development

Our Approach
Tests in Development
Cutaneous Squamous Cell Carcinoma
Suspicious Pigmented Lesions

Latest News & Publications

Press Releases
Scientific Publications
Email Alerts

Resources

Healthcare Professionals
Patients

Copyright © 2020 Castle Biosciences, Inc. | All Rights Reserved

Privacy Policy
Terms of Use
Contact Us

7ads6x98y